Biomarkers in the pharmaceutical industry
Clin Chem
.
2015 Apr;61(4):579-83.
doi: 10.1373/clinchem.2014.225284.
Epub 2014 Nov 6.
Authors
Omar F Laterza
1
,
Andrew Plump
2
,
Jeffrey E Ming
3
,
Susan Richards
4
,
Michael E Ransom Burczynski
5
,
John A Wagner
6
,
Scott D Patterson
7
Affiliations
1
Director, Immunochemistry and Mass Spectrometry, Molecular Biomarkers and Diagnostics, Merck Research Laboratories, Rahway, NJ;
[email protected]
.
2
Senior Vice President, Deputy to the President, Research & Translational Medicine, Sanofi, Paris, France;
3
Senior Director, Clinical & Exploratory Pharmacology, Sanofi, Bridgewater, NJ;
4
Group Vice President, Clinical Laboratory Sciences, Disposition, Safety and Animal Research, Sanofi, Framingham, MA;
5
Executive Director, Biomarker Technologies, Bristol-Myers Squibb Co., Lawrenceville, NJ;
6
Vice President and Head of Global Experimental Medicine, Takeda Pharmaceuticals, Cambridge, MA;
7
Executive Director, Medical Sciences, Amgen, Thousand Oaks, CA.
PMID:
25376580
DOI:
10.1373/clinchem.2014.225284
No abstract available
MeSH terms
Biomarkers / analysis*
Humans
Pharmaceutical Preparations / analysis*
Quality Control
Substances
Biomarkers
Pharmaceutical Preparations